Zhenyu Ding

6.1k citations
83 papers · 5k · 2 hit papers · h-index 24

Impact in

Papers in

    • Cancer Immunotherapy and Biomarkers 20
    • Immunotherapy and Immune Responses 20

Zhenyu Ding

80 papers receiving 4.9k citations

Zhenyu Ding's Hit Papers

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer 2020 · 448 citations
4480+2+4Years since publication5001k1.5k2k2.5k

Peers

Zhenyu Ding
Comparison fields: 5 of 97
  • Oncology 2.7k
  • Pulmonary and Respiratory Medicine 1.1k
  • Immunology 487
  • Cancer Research 155
  • Molecular Biology 671
Replace Akin Atmaca with:
Akin Atmaca Germany
Yann Alexandre Vano France
Hisatsugu Goto Japan
Asim Amin United States
Rachel E. Sanborn United States
Ramy A. Ibrahim United States
Micaela Hernberg Finland
Charlotte M. Roach United States
Dawei Chen China
Kevin Gergich United States
Zhenyu Ding relative to Akin Atmaca Germany Akin Atmaca's profile →
Citations per field
00.5×1.5×2.1×
Akin Atmaca · 1×
Citations per year

Countries citing papers authored by Zhenyu Ding

Since Specialization
Citations

This map shows the geographic impact of Zhenyu Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenyu Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenyu Ding more than expected).

Fields of papers citing papers by Zhenyu Ding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenyu Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenyu Ding. The network helps show where Zhenyu Ding may publish in the future.

Co-authors

The 25 scholars most cited alongside Zhenyu Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Zhenyu Ding Line = papers co-authored together Zhenyu Ding links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 83 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Hit paper breakdown →
20192712
2
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
Hit paper breakdown →
2020448
3 2021218
4 2021138
5 202090
6 201988
7 201276
8 201973
9 201866
10 202164
11 201962
12 200560
13 200436
14 202235
15 202034
16 201931
17 201630
18 200428
19 201828
20 202026

About Zhenyu Ding

Zhenyu Ding is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Surgery and Cancer Research, having authored 83 papers that have together received 5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (20 papers), Immunotherapy and Immune Responses (20 papers), Lung Cancer Treatments and Mutations (9 papers), Esophageal Cancer Research and Treatment (7 papers), Brain Metastases and Treatment (5 papers), Cell death mechanisms and regulation (5 papers), Virus-based gene therapy research (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). The work is most often cited by research in Oncology (2.7k citations), Pulmonary and Respiratory Medicine (1.1k citations), Immunology (487 citations), Cancer Research (155 citations) and Molecular Biology (671 citations). Zhenyu Ding has collaborated with scholars based in China, Sweden and United States. Frequent co-authors include Jiyan Liu, Guihong Liu, Peipei Wang, Yuquan Wei, Qing Li, Yueyun Chen, Tao Chen, Xiawei Wei, Yang Wang and Yang Fu. Their work appears in journals such as Frontiers in Pharmacology, Signal Transduction and Targeted Therapy, BMC Cancer, International Journal of Oncology and Frontiers in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact